文献速递头颈与中枢神经肿瘤

EGCG对缓解期鼻咽癌患者EBV再激活影响的随机试验

A randomized trial to evaluate the effect of epigallocatechin gallate (EGCG) on EBV reactivation in patients with nasopharyngeal carcinoma in remission -the TCOG T2312 study.
PubMed 文献 · Eur J Cancer · 2026-10-01

本研究为随机对照试验,纳入353例经放疗达完全缓解且血浆EBV DNA阴性的鼻咽癌患者,随机接受EGCG或安慰剂治疗3年。结果显示EGCG未能降低EBV再激活率或复发率,但血浆EBV DNA阳性与高复发率及较短的无复发生存和总生存显著相关。

要点

  • EGCG在缓解期鼻咽癌患者中未能降低EBV再激活或肿瘤复发。
  • 血浆EBV DNA阳性与高复发率及较短RFS和OS显著相关。
  • 建议持续监测血浆EBV DNA作为鼻咽癌患者的随访标志物。

核心结论

  • EGCG未能减少缓解期鼻咽癌患者的EBV再激活和肿瘤复发,但EBV DNA是肿瘤复发、RFS和OS的预后因素。

研究设计与样本

  • 随机对照试验,纳入353例经放疗达完全缓解且血浆EBV DNA阴性的鼻咽癌患者,327例可评估,EGCG组161例、安慰剂组166例,治疗3年。

主要发现

  • EGCG毒性极小且耐受良好,两组EBV DNA再激活率或复发率无显著差异。
  • 血浆EBV DNA阳性与高复发率及较短的无复发生存和总生存时间显著相关。

临床怎么用

  • 不建议使用EGCG预防缓解期鼻咽癌患者的EBV再激活,建议持续随访监测血浆EBV DNA作为 surveillance 标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nasopharyngeal carcinoma (NPC) is associated with Epstein-Barr virus (EBV) infection. Epigallocatechin gallate (EGCG), a major effective compound in green tea extract, inhibits EBV reactivation. We conducted a randomized controlled trial to evaluate the effects of EGCG on EBV reactivation in posttreatment NPC patients in remission status. METHODS: Patients with NPC who received radiation-based treatment and who achieved a complete response with negative plasma EBV DNA results were randomized to receive EGCG or placebo for 3 years. EBV-related antibodies and EBV DNA were monitored periodically. The primary objective was the EBV reactivation rate and the secondary objectives were safety of EGCG and correlation between EBV reactivation and clinical outcomes. RESULTS: A total of 353 patients were included in this study, of whom 327 were evaluable for further analyses. Of these, 161 and 166 patients were randomized to receive EGCG and placebo, respectively. The toxicity of EGCG was minimal and well tolerated. No significant difference was observed in the EBV DNA reactivation or recurrence rate between the two groups. Positive plasma EBV DNA was significantly associated with a high recurrence rate and short recurrence-free survival (RFS) and overall survival (OS) times. CONCLUSION: This study failed to demonstrate the ability of EGCG to reduce EBV reactivation and tumor recurrence in NPC patients in remission. However, the results showed that EBV DNA is a prognostic factor for tumor recurrence, RFS, and OS in these patients. Continuous follow-up of plasma EBV DNA is suggested as a surveillance marker for patients with NPC. (NCT01744587).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Tsai HJ, Cheng SH, Yang SN, et al. A randomized trial to evaluate the effect of epigallocatechin gallate (EGCG) on EBV reactivation in patients with nasopharyngeal carcinoma in remission -the TCOG T2312 study. Eur J Cancer. 2026. PMID: 42833136. doi:10.1016/j.ejca.2026.117445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。